Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
52
AXSM Quote, Financials, Valuation and Earnings
Last price:
$168.52
Seasonality move
:
23.95%
Day range:
$166.65 - $171.22
52-week range:
$86.99 - $191.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.88x
P/B ratio:
95.77x
Volume:
617K
Avg. volume:
629.7K
1-year change:
53.54%
Market cap:
$8.5B
Revenue:
$638.5M
EPS (TTM):
-$3.69
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$225.4M | -$0.55 | 50.24% | -36.43% | $223.66 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$305.2M | $0.12 | 15.35% | -21.66% | $31.85 |
|
FOLD
Amicus Therapeutics, Inc.
|
$180.9M | $0.02 | 16.93% | 267.32% | $14.50 |
|
INSM
Insmed, Inc.
|
$385.6M | -$0.81 | 259.02% | -30.12% | $214.32 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$348.5M | -$1.41 | 63.79% | -25% | $668.57 |
|
MNKD
MannKind Corp.
|
$112.5M | $0.02 | 36.93% | -59.34% | $7.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$168.51 | $223.66 | $8.5B | -- | $0.00 | 0% | 12.88x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.44 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.06x |
|
INSM
Insmed, Inc.
|
$162.43 | $214.32 | $34.5B | -- | $0.00 | 0% | 53.27x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$546.89 | $668.57 | $13B | -- | $0.00 | 0% | 13.20x |
|
MNKD
MannKind Corp.
|
$2.50 | $7.50 | $753.6M | 145.59x | $0.00 | 0% | 2.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
71.18% | -0.449 | 2.35% | 1.44x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -1.478 | 9.99% | 1.72x |
|
INSM
Insmed, Inc.
|
50.57% | 1.883 | 2.03% | 3.35x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
36.58% | -1.826 | 2.61% | 3.62x |
|
MNKD
MannKind Corp.
|
112.08% | 1.908 | 27.12% | 1.23x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$181.4M | -$36M | -64.52% | -265.23% | -18.38% | -$18.7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$296.2M | -$59.6M | -32.42% | -42.53% | -18.57% | -$133.1M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
Axsome Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AXSM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -14.57% compared to Axsome Therapeutics, Inc.'s net margin of 96.33%. Axsome Therapeutics, Inc.'s return on equity of -265.23% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About AXSM or ACAD?
Axsome Therapeutics, Inc. has a consensus price target of $223.66, signalling upside risk potential of 32.73%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.17 1 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is AXSM or ACAD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.479, which suggesting that the stock is 52.123% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock AXSM or ACAD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or ACAD?
Axsome Therapeutics, Inc. quarterly revenues are $196M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Axsome Therapeutics, Inc.'s net income of -$28.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.88x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns AXSM or FOLD?
Amicus Therapeutics, Inc. has a net margin of -14.57% compared to Axsome Therapeutics, Inc.'s net margin of 0.91%. Axsome Therapeutics, Inc.'s return on equity of -265.23% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About AXSM or FOLD?
Axsome Therapeutics, Inc. has a consensus price target of $223.66, signalling upside risk potential of 32.73%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Axsome Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.17 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is AXSM or FOLD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.479, which suggesting that the stock is 52.123% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.
-
Which is a Better Dividend Stock AXSM or FOLD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or FOLD?
Axsome Therapeutics, Inc. quarterly revenues are $196M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Axsome Therapeutics, Inc.'s net income of -$28.6M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.88x versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M FOLDAmicus Therapeutics, Inc.7.06x -- $185.2M $1.7M
-
Which has Higher Returns AXSM or INSM?
Insmed, Inc. has a net margin of -14.57% compared to Axsome Therapeutics, Inc.'s net margin of -124.5%. Axsome Therapeutics, Inc.'s return on equity of -265.23% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About AXSM or INSM?
Axsome Therapeutics, Inc. has a consensus price target of $223.66, signalling upside risk potential of 32.73%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that Axsome Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.17 1 0 INSMInsmed, Inc.17 0 0 -
Is AXSM or INSM More Risky?
Axsome Therapeutics, Inc. has a beta of 0.479, which suggesting that the stock is 52.123% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.
-
Which is a Better Dividend Stock AXSM or INSM?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or INSM?
Axsome Therapeutics, Inc. quarterly revenues are $196M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Axsome Therapeutics, Inc.'s net income of -$28.6M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.88x versus 53.27x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M INSMInsmed, Inc.53.27x -- $263.8M -$328.5M
-
Which has Higher Returns AXSM or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -14.57% compared to Axsome Therapeutics, Inc.'s net margin of -18.24%. Axsome Therapeutics, Inc.'s return on equity of -265.23% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M MDGLMadrigal Pharmaceuticals, Inc.92.26% -$2.57 $950.3M -
What do Analysts Say About AXSM or MDGL?
Axsome Therapeutics, Inc. has a consensus price target of $223.66, signalling upside risk potential of 32.73%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 22.25%. Given that Axsome Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.17 1 0 MDGLMadrigal Pharmaceuticals, Inc.11 2 0 -
Is AXSM or MDGL More Risky?
Axsome Therapeutics, Inc. has a beta of 0.479, which suggesting that the stock is 52.123% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.
-
Which is a Better Dividend Stock AXSM or MDGL?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or MDGL?
Axsome Therapeutics, Inc. quarterly revenues are $196M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Axsome Therapeutics, Inc.'s net income of -$28.6M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.88x versus 13.20x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M MDGLMadrigal Pharmaceuticals, Inc.13.20x -- $321.1M -$58.6M
-
Which has Higher Returns AXSM or MNKD?
MannKind Corp. has a net margin of -14.57% compared to Axsome Therapeutics, Inc.'s net margin of -14.25%. Axsome Therapeutics, Inc.'s return on equity of -265.23% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About AXSM or MNKD?
Axsome Therapeutics, Inc. has a consensus price target of $223.66, signalling upside risk potential of 32.73%. On the other hand MannKind Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 200%. Given that MannKind Corp. has higher upside potential than Axsome Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.17 1 0 MNKDMannKind Corp.8 1 0 -
Is AXSM or MNKD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.479, which suggesting that the stock is 52.123% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.225%.
-
Which is a Better Dividend Stock AXSM or MNKD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or MNKD?
Axsome Therapeutics, Inc. quarterly revenues are $196M, which are larger than MannKind Corp. quarterly revenues of $112M. Axsome Therapeutics, Inc.'s net income of -$28.6M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 145.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.88x versus 2.19x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M MNKDMannKind Corp.2.19x 145.59x $112M -$15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
